摘要
目的探讨超声介入微波消融术联合仑伐替尼治疗原发性小肝癌的临床疗效。方法纳入88例原发性小肝癌患者为研究对象,按照随机数字表法分为观察组和对照组,各44例。对照组患者行超声介入微波消融术治疗,观察组在此基础上联合仑伐替尼治疗,观察两组临床疗效、血清甲胎蛋白、肝功能[天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)及白蛋白(ALB)]、不良反应发生情况及术后1年复发情况。结果观察组术后9周短期疗效100%,与对照组(97.73%)比较,差异无统计学意义(χ^(2)=1.000,P>0.05);随访12个月,观察组复发率(2.27%)低于对照组(27.27%),差异有统计学意义(χ^(2)=10.921,P<0.05);治疗后,观察组AST(38.29±5.23)U/L、ALT(52.21±5.78)U/L,与对照组AST(45.21±5.38)U/L、ALT(57.25±5.56)U/L比较,差异有统计学意义(t=6.121、4.167,P均<0.05),观察组ALB(29.85±1.61)g/L、AFP(18.21±2.25)μg/L,与对照组ALB(28.42±1.57)g/L、AFP(23.12±2.12)μg/L比较,差异有统计学意义(t=4.244、10.539,P均<0.05);观察组用药期间总不良反应发生率为11.36%,经干预均好转。结论相较于单纯超声介入微波消融术治疗,其与仑伐替尼联合治疗原发性小肝癌的短期疗效相当,但联合治疗可改善患者肝功能损伤,明显降低患者肿瘤复发率。
Objective To explore the clinical efficacy of ultrasound intervention microwave ablation combined with lenvatinib in the treatment of primary small liver cancer.Methods 88 patients with primary small liver cancer were the study subjects.They were divided into the observation group and the control group using a random number table method,with 44 patients in each group.The patients in the control group were treated with ultrasonic intervention microwave ablation,and the observation group was treated with lenvatinib on this basis.The clinical efficacy,serum alpha fetoprotein,liver function[aspartate transaminase(AST),alanine transaminase(ALT)and albumin(ALB)],adverse reactions and recurrence 1 year after operation were observed in the 2 groups.Results The short-term efficacy of the observation group at 9 weeks after surgery was 100%,and there was no statistical significant difference compared to the control group(97.73%)(χ^(2)=1.000,P>0.05).Following up for 12 months,the recurrence rate in the observation group was(2.27%)lower than that in the control group(27.27%),with a statistical significant difference(χ^(2)=10.921,P<0.05).After treatment,the AST(38.29±5.23)U/L and ALT(52.21±5.78)U/L in the observation group were statistically significant compared to the AST(45.21±5.38)U/L and ALT(57.25±5.56)U/L in the control group(t=6.121,4.167,P<0.05).The observation group showed statistical significant differences in ALB(29.85±1.61)g/L and AFP(18.21±2.25)μg/L compared to the control group(28.42±1.57)g/L and AFP(23.12±2.12)μg/L(t=4.244,10.539,P<0.05).The total incidence of adverse reactions during the medication period in the observation group was 11.36%,which improved after intervention.Conclusion Compared to simple ultrasound intervention microwave ablation therapy,its short-term efficacy is comparable to that of the combination therapy of lenvatinib for primary small liver cancer.However,the combination therapy can improve liver function damage in patients and significantly reduce tumor recurrence rate.
作者
杜轲锋
邵亚丽
DU Kefeng;SHAO Yali(Luohe Central Hospital,Luohe,462000)
出处
《实用癌症杂志》
2024年第2期270-273,共4页
The Practical Journal of Cancer
关键词
原发性小肝癌
超声介入微波消融术
仑伐替尼
Primary small liver cancer
Ultrasound intervention microwave ablation
Lenvatinib
